img

Global Generic Anti-cancer Injectables Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Generic Anti-cancer Injectables Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal Generic Anti-cancer Injectables Market
Global Generic Anti-cancer Injectables market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Generic Anti-cancer Injectables industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Generic Anti-cancer Injectables key companies include Teva, Viatris, Biocon, Amgen, Sandoz (Novartis), Pfizer, Qilu Pharmaceutical, Jiangsu Hansoh and CTTQ, etc. Teva, Viatris, Biocon are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Generic Anti-cancer Injectables were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Generic Anti-cancer Injectables market and estimated to attract more attentions from industry insiders and investors.
Generic Anti-cancer Injectables can be divided into Bevacizuma, Rituximab, Herceptin and Paclitaxel, etc. Bevacizuma is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Generic Anti-cancer Injectables is widely used in various fields, such as Hospital and Retail, etc. Hospital provides greatest supports to the Generic Anti-cancer Injectables industry development. In 2022, global % revenue of Generic Anti-cancer Injectables went into Hospital filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Generic Anti-cancer Injectables market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Generic Anti-cancer Injectables market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
Segment by Type
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others

Segment by Application


Hospital
Retail
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Generic Anti-cancer Injectables introduction, etc. Generic Anti-cancer Injectables Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Generic Anti-cancer Injectables
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Bevacizuma
1.2.3 Rituximab
1.2.4 Herceptin
1.2.5 Paclitaxel
1.2.6 Others
1.3 Market by Application
1.3.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Generic Anti-cancer Injectables Market Perspective (2018-2029)
2.2 Global Generic Anti-cancer Injectables Growth Trends by Region
2.2.1 Generic Anti-cancer Injectables Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Generic Anti-cancer Injectables Historic Market Size by Region (2018-2024)
2.2.3 Generic Anti-cancer Injectables Forecasted Market Size by Region (2024-2029)
2.3 Generic Anti-cancer Injectables Market Dynamics
2.3.1 Generic Anti-cancer Injectables Industry Trends
2.3.2 Generic Anti-cancer Injectables Market Drivers
2.3.3 Generic Anti-cancer Injectables Market Challenges
2.3.4 Generic Anti-cancer Injectables Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Generic Anti-cancer Injectables by Players
3.1.1 Global Generic Anti-cancer Injectables Revenue by Players (2018-2024)
3.1.2 Global Generic Anti-cancer Injectables Revenue Market Share by Players (2018-2024)
3.2 Global Generic Anti-cancer Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Generic Anti-cancer Injectables, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Generic Anti-cancer Injectables Market Concentration Ratio
3.4.1 Global Generic Anti-cancer Injectables Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic Anti-cancer Injectables Revenue in 2022
3.5 Global Key Players of Generic Anti-cancer Injectables Head office and Area Served
3.6 Global Key Players of Generic Anti-cancer Injectables, Product and Application
3.7 Global Key Players of Generic Anti-cancer Injectables, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic Anti-cancer Injectables Breakdown Data by Type
4.1 Global Generic Anti-cancer Injectables Historic Market Size by Type (2018-2024)
4.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2024-2029)
5 Generic Anti-cancer Injectables Breakdown Data by Application
5.1 Global Generic Anti-cancer Injectables Historic Market Size by Application (2018-2024)
5.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Generic Anti-cancer Injectables Market Size (2018-2029)
6.2 North America Generic Anti-cancer Injectables Market Size by Type
6.2.1 North America Generic Anti-cancer Injectables Market Size by Type (2018-2024)
6.2.2 North America Generic Anti-cancer Injectables Market Size by Type (2024-2029)
6.2.3 North America Generic Anti-cancer Injectables Market Share by Type (2018-2029)
6.3 North America Generic Anti-cancer Injectables Market Size by Application
6.3.1 North America Generic Anti-cancer Injectables Market Size by Application (2018-2024)
6.3.2 North America Generic Anti-cancer Injectables Market Size by Application (2024-2029)
6.3.3 North America Generic Anti-cancer Injectables Market Share by Application (2018-2029)
6.4 North America Generic Anti-cancer Injectables Market Size by Country
6.4.1 North America Generic Anti-cancer Injectables Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Generic Anti-cancer Injectables Market Size by Country (2018-2024)
6.4.3 North America Generic Anti-cancer Injectables Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Generic Anti-cancer Injectables Market Size (2018-2029)
7.2 Europe Generic Anti-cancer Injectables Market Size by Type
7.2.1 Europe Generic Anti-cancer Injectables Market Size by Type (2018-2024)
7.2.2 Europe Generic Anti-cancer Injectables Market Size by Type (2024-2029)
7.2.3 Europe Generic Anti-cancer Injectables Market Share by Type (2018-2029)
7.3 Europe Generic Anti-cancer Injectables Market Size by Application
7.3.1 Europe Generic Anti-cancer Injectables Market Size by Application (2018-2024)
7.3.2 Europe Generic Anti-cancer Injectables Market Size by Application (2024-2029)
7.3.3 Europe Generic Anti-cancer Injectables Market Share by Application (2018-2029)
7.4 Europe Generic Anti-cancer Injectables Market Size by Country
7.4.1 Europe Generic Anti-cancer Injectables Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Generic Anti-cancer Injectables Market Size by Country (2018-2024)
7.4.3 Europe Generic Anti-cancer Injectables Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Generic Anti-cancer Injectables Market Size (2018-2029)
8.2 China Generic Anti-cancer Injectables Market Size by Type
8.2.1 China Generic Anti-cancer Injectables Market Size by Type (2018-2024)
8.2.2 China Generic Anti-cancer Injectables Market Size by Type (2024-2029)
8.2.3 China Generic Anti-cancer Injectables Market Share by Type (2018-2029)
8.3 China Generic Anti-cancer Injectables Market Size by Application
8.3.1 China Generic Anti-cancer Injectables Market Size by Application (2018-2024)
8.3.2 China Generic Anti-cancer Injectables Market Size by Application (2024-2029)
8.3.3 China Generic Anti-cancer Injectables Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Generic Anti-cancer Injectables Market Size (2018-2029)
9.2 Asia Generic Anti-cancer Injectables Market Size by Type
9.2.1 Asia Generic Anti-cancer Injectables Market Size by Type (2018-2024)
9.2.2 Asia Generic Anti-cancer Injectables Market Size by Type (2024-2029)
9.2.3 Asia Generic Anti-cancer Injectables Market Share by Type (2018-2029)
9.3 Asia Generic Anti-cancer Injectables Market Size by Application
9.3.1 Asia Generic Anti-cancer Injectables Market Size by Application (2018-2024)
9.3.2 Asia Generic Anti-cancer Injectables Market Size by Application (2024-2029)
9.3.3 Asia Generic Anti-cancer Injectables Market Share by Application (2018-2029)
9.4 Asia Generic Anti-cancer Injectables Market Size by Region
9.4.1 Asia Generic Anti-cancer Injectables Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Generic Anti-cancer Injectables Market Size by Region (2018-2024)
9.4.3 Asia Generic Anti-cancer Injectables Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Type
10.2.1 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Application
10.3.1 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Country
10.4.1 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Details
11.1.2 Teva Business Overview
11.1.3 Teva Generic Anti-cancer Injectables Introduction
11.1.4 Teva Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.1.5 Teva Recent Developments
11.2 Viatris
11.2.1 Viatris Company Details
11.2.2 Viatris Business Overview
11.2.3 Viatris Generic Anti-cancer Injectables Introduction
11.2.4 Viatris Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.2.5 Viatris Recent Developments
11.3 Biocon
11.3.1 Biocon Company Details
11.3.2 Biocon Business Overview
11.3.3 Biocon Generic Anti-cancer Injectables Introduction
11.3.4 Biocon Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.3.5 Biocon Recent Developments
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Generic Anti-cancer Injectables Introduction
11.4.4 Amgen Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.4.5 Amgen Recent Developments
11.5 Sandoz (Novartis)
11.5.1 Sandoz (Novartis) Company Details
11.5.2 Sandoz (Novartis) Business Overview
11.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Introduction
11.5.4 Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.5.5 Sandoz (Novartis) Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Generic Anti-cancer Injectables Introduction
11.6.4 Pfizer Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.6.5 Pfizer Recent Developments
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Company Details
11.7.2 Qilu Pharmaceutical Business Overview
11.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Introduction
11.7.4 Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.7.5 Qilu Pharmaceutical Recent Developments
11.8 Jiangsu Hansoh
11.8.1 Jiangsu Hansoh Company Details
11.8.2 Jiangsu Hansoh Business Overview
11.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Introduction
11.8.4 Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.8.5 Jiangsu Hansoh Recent Developments
11.9 CTTQ
11.9.1 CTTQ Company Details
11.9.2 CTTQ Business Overview
11.9.3 CTTQ Generic Anti-cancer Injectables Introduction
11.9.4 CTTQ Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.9.5 CTTQ Recent Developments
11.10 Jiangsu Hengrui
11.10.1 Jiangsu Hengrui Company Details
11.10.2 Jiangsu Hengrui Business Overview
11.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Introduction
11.10.4 Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.10.5 Jiangsu Hengrui Recent Developments
11.11 CSPC
11.11.1 CSPC Company Details
11.11.2 CSPC Business Overview
11.11.3 CSPC Generic Anti-cancer Injectables Introduction
11.11.4 CSPC Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.11.5 CSPC Recent Developments
11.12 Innovent Biologics
11.12.1 Innovent Biologics Company Details
11.12.2 Innovent Biologics Business Overview
11.12.3 Innovent Biologics Generic Anti-cancer Injectables Introduction
11.12.4 Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2018-2024)
11.12.5 Innovent Biologics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Generic Anti-cancer Injectables Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Bevacizuma
Table 3. Key Players of Rituximab
Table 4. Key Players of Herceptin
Table 5. Key Players of Paclitaxel
Table 6. Key Players of Others
Table 7. Global Generic Anti-cancer Injectables Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 8. Global Generic Anti-cancer Injectables Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Generic Anti-cancer Injectables Market Size by Region (2018-2024) & (US$ Million)
Table 10. Global Generic Anti-cancer Injectables Market Share by Region (2018-2024)
Table 11. Global Generic Anti-cancer Injectables Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Generic Anti-cancer Injectables Market Share by Region (2024-2029)
Table 13. Generic Anti-cancer Injectables Market Trends
Table 14. Generic Anti-cancer Injectables Market Drivers
Table 15. Generic Anti-cancer Injectables Market Challenges
Table 16. Generic Anti-cancer Injectables Market Restraints
Table 17. Global Generic Anti-cancer Injectables Revenue by Players (2018-2024) & (US$ Million)
Table 18. Global Generic Anti-cancer Injectables Revenue Share by Players (2018-2024)
Table 19. Global Top Generic Anti-cancer Injectables by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2022)
Table 20. Global Generic Anti-cancer Injectables Industry Ranking 2021 VS 2022 VS 2024
Table 21. Global 5 Largest Players Market Share by Generic Anti-cancer Injectables Revenue (CR5 and HHI) & (2018-2024)
Table 22. Global Key Players of Generic Anti-cancer Injectables, Headquarters and Area Served
Table 23. Global Key Players of Generic Anti-cancer Injectables, Product and Application
Table 24. Global Key Players of Generic Anti-cancer Injectables, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Generic Anti-cancer Injectables Market Size by Type (2018-2024) & (US$ Million)
Table 27. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2018-2024)
Table 28. Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2024-2029)
Table 30. Global Generic Anti-cancer Injectables Market Size by Application (2018-2024) & (US$ Million)
Table 31. Global Generic Anti-cancer Injectables Revenue Share by Application (2018-2024)
Table 32. Global Generic Anti-cancer Injectables Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Generic Anti-cancer Injectables Revenue Share by Application (2024-2029)
Table 34. North America Generic Anti-cancer Injectables Market Size by Type (2018-2024) & (US$ Million)
Table 35. North America Generic Anti-cancer Injectables Market Size by Type (2024-2029) & (US$ Million)
Table 36. North America Generic Anti-cancer Injectables Market Size by Application (2018-2024) & (US$ Million)
Table 37. North America Generic Anti-cancer Injectables Market Size by Application (2024-2029) & (US$ Million)
Table 38. North America Generic Anti-cancer Injectables Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. North America Generic Anti-cancer Injectables Market Size by Country (2018-2024) & (US$ Million)
Table 40. North America Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US$ Million)
Table 41. Europe Generic Anti-cancer Injectables Market Size by Type (2018-2024) & (US$ Million)
Table 42. Europe Generic Anti-cancer Injectables Market Size by Type (2024-2029) & (US$ Million)
Table 43. Europe Generic Anti-cancer Injectables Market Size by Application (2018-2024) & (US$ Million)
Table 44. Europe Generic Anti-cancer Injectables Market Size by Application (2024-2029) & (US$ Million)
Table 45. Europe Generic Anti-cancer Injectables Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Europe Generic Anti-cancer Injectables Market Size by Country (2018-2024) & (US$ Million)
Table 47. Europe Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US$ Million)
Table 48. China Generic Anti-cancer Injectables Market Size by Type (2018-2024) & (US$ Million)
Table 49. China Generic Anti-cancer Injectables Market Size by Type (2024-2029) & (US$ Million)
Table 50. China Generic Anti-cancer Injectables Market Size by Application (2018-2024) & (US$ Million)
Table 51. China Generic Anti-cancer Injectables Market Size by Application (2024-2029) & (US$ Million)
Table 52. Asia Generic Anti-cancer Injectables Market Size by Type (2018-2024) & (US$ Million)
Table 53. Asia Generic Anti-cancer Injectables Market Size by Type (2024-2029) & (US$ Million)
Table 54. Asia Generic Anti-cancer Injectables Market Size by Application (2018-2024) & (US$ Million)
Table 55. Asia Generic Anti-cancer Injectables Market Size by Application (2024-2029) & (US$ Million)
Table 56. Asia Generic Anti-cancer Injectables Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Asia Generic Anti-cancer Injectables Market Size by Region (2018-2024) & (US$ Million)
Table 58. Asia Generic Anti-cancer Injectables Market Size by Region (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Type (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Type (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Application (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Application (2024-2029) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 64. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Country (2018-2024) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US$ Million)
Table 66. Teva Company Details
Table 67. Teva Business Overview
Table 68. Teva Generic Anti-cancer Injectables Product
Table 69. Teva Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 70. Teva Recent Developments
Table 71. Viatris Company Details
Table 72. Viatris Business Overview
Table 73. Viatris Generic Anti-cancer Injectables Product
Table 74. Viatris Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 75. Viatris Recent Developments
Table 76. Biocon Company Details
Table 77. Biocon Business Overview
Table 78. Biocon Generic Anti-cancer Injectables Product
Table 79. Biocon Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 80. Biocon Recent Developments
Table 81. Amgen Company Details
Table 82. Amgen Business Overview
Table 83. Amgen Generic Anti-cancer Injectables Product
Table 84. Amgen Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 85. Amgen Recent Developments
Table 86. Sandoz (Novartis) Company Details
Table 87. Sandoz (Novartis) Business Overview
Table 88. Sandoz (Novartis) Generic Anti-cancer Injectables Product
Table 89. Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 90. Sandoz (Novartis) Recent Developments
Table 91. Pfizer Company Details
Table 92. Pfizer Business Overview
Table 93. Pfizer Generic Anti-cancer Injectables Product
Table 94. Pfizer Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 95. Pfizer Recent Developments
Table 96. Qilu Pharmaceutical Company Details
Table 97. Qilu Pharmaceutical Business Overview
Table 98. Qilu Pharmaceutical Generic Anti-cancer Injectables Product
Table 99. Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 100. Qilu Pharmaceutical Recent Developments
Table 101. Jiangsu Hansoh Company Details
Table 102. Jiangsu Hansoh Business Overview
Table 103. Jiangsu Hansoh Generic Anti-cancer Injectables Product
Table 104. Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 105. Jiangsu Hansoh Recent Developments
Table 106. CTTQ Company Details
Table 107. CTTQ Business Overview
Table 108. CTTQ Generic Anti-cancer Injectables Product
Table 109. CTTQ Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 110. CTTQ Recent Developments
Table 111. Jiangsu Hengrui Company Details
Table 112. Jiangsu Hengrui Business Overview
Table 113. Jiangsu Hengrui Generic Anti-cancer Injectables Product
Table 114. Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 115. Jiangsu Hengrui Recent Developments
Table 116. CSPC Company Details
Table 117. CSPC Business Overview
Table 118. CSPC Generic Anti-cancer Injectables Product
Table 119. CSPC Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 120. CSPC Recent Developments
Table 121. Innovent Biologics Company Details
Table 122. Innovent Biologics Business Overview
Table 123. Innovent Biologics Generic Anti-cancer Injectables Product
Table 124. Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2018-2024) & (US$ Million)
Table 125. Innovent Biologics Recent Developments
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Generic Anti-cancer Injectables Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Generic Anti-cancer Injectables Market Share by Type: 2022 VS 2029
Figure 3. Bevacizuma Features
Figure 4. Rituximab Features
Figure 5. Herceptin Features
Figure 6. Paclitaxel Features
Figure 7. Others Features
Figure 8. Global Generic Anti-cancer Injectables Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Generic Anti-cancer Injectables Market Share by Application: 2022 VS 2029
Figure 10. Hospital Case Studies
Figure 11. Retail Case Studies
Figure 12. Generic Anti-cancer Injectables Report Years Considered
Figure 13. Global Generic Anti-cancer Injectables Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Generic Anti-cancer Injectables Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Generic Anti-cancer Injectables Market Share by Region: 2022 VS 2029
Figure 16. Global Generic Anti-cancer Injectables Market Share by Players in 2022
Figure 17. Global Top Generic Anti-cancer Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Generic Anti-cancer Injectables Revenue in 2022
Figure 19. North America Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Generic Anti-cancer Injectables Market Share by Type (2018-2029)
Figure 21. North America Generic Anti-cancer Injectables Market Share by Application (2018-2029)
Figure 22. North America Generic Anti-cancer Injectables Market Share by Country (2018-2029)
Figure 23. United States Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Generic Anti-cancer Injectables Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Generic Anti-cancer Injectables Market Share by Type (2018-2029)
Figure 27. Europe Generic Anti-cancer Injectables Market Share by Application (2018-2029)
Figure 28. Europe Generic Anti-cancer Injectables Market Share by Country (2018-2029)
Figure 29. Germany Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Generic Anti-cancer Injectables Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Generic Anti-cancer Injectables Market Share by Type (2018-2029)
Figure 37. China Generic Anti-cancer Injectables Market Share by Application (2018-2029)
Figure 38. Asia Generic Anti-cancer Injectables Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Generic Anti-cancer Injectables Market Share by Type (2018-2029)
Figure 40. Asia Generic Anti-cancer Injectables Market Share by Application (2018-2029)
Figure 41. Asia Generic Anti-cancer Injectables Market Share by Region (2018-2029)
Figure 42. Japan Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Generic Anti-cancer Injectables Market Share by Country (2018-2029)
Figure 52. Brazil Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Teva Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 59. Viatris Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 60. Biocon Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 61. Amgen Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 62. Sandoz (Novartis) Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 63. Pfizer Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 64. Qilu Pharmaceutical Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 65. Jiangsu Hansoh Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 66. CTTQ Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 67. Jiangsu Hengrui Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 68. CSPC Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 69. Innovent Biologics Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2024)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries